Leadership
David Cheresh, PhD
Scientific Founder & Advisor
UCSD Pathology Vice Chair. Developed Unituxin (FDA 2015). TargeGen founder (Fedratinib FDA 2019, $7B exit). 26 issued patents.
Sara Weis, PhD
VP of Research & Co-Founder
Drives discovery, translational biology, and the Fibrozumab IND-enabling research roadmap.
Stephen J. McCormack, PhD
CEO & Co-Founder
Veteran biotech operator. Built MannKind ($2B), CytomX ($1.5B), AlleCure (ALK exit), NeuroSystec, Pixium Vision (now Science Corp).
Kamal Egodage, PhD
Chief Manufacturing Officer
Leads CMC, biologics process development, scale-up and clinical supply for Fibrozumab.
Alfred Atallah, Esq.
Legal Advisor
Heads corporate, IP, and transactional matters supporting financing, patents, and partnerships.
Advisory Board
Michael Karin, PhD
UCSD / NAS member
Tumor inflammation, fibrosis biology.
Andrew Lowy, MD
UCSD Surgical Oncology
Head of Surgical Oncology, PDAC clinical trials.
Bassel El-Rayes, MD
UCSD Health
Deputy Director, Moores Cancer Center.
Dan Von Hoff, MD
Mayo Clinic, Arizona
World renown Pancreas Cancer physician scientist.
David Brenner, MD
Sanford Burnham Prebys CEO
Liver fibrosis & clinical trials.
David Cheresh, PhD
UCSD Research
Scientific founder — angiogenesis, integrins.
Doug Frankel
Executive Vice President, National Search Associates